vinblastine,Dacarbazine,nivolumab,doxorubicin
bms
['lymsm', 'cml']
phase 2 n-avd x 6 in older adults with chl #17icml (geri assessment included!)
- 33 pts (most with comorbidities &amp; polypharmacy)
- 2-yr pfs 86%, os 96% (!!!)
- no deaths attributed to chl
- geri syndromes not correlated with outcomes/aes
phenomenal &amp; clin-relevant study! #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈